
    
      Primary Objective - Determine overall response rate (ORR) in patients treated with CNP

      Secondary Objective(s)

        -  Determine progression-free survival (PFS), and disease control rate (DCR) in patients
           treated with CNP.

        -  Determine duration of response in patients treated with CNP.

        -  Determine safety/tolerability of CNP.

      Correlative Endpoints

      - Identify pathologic and genomic correlates of response to CNP.

      Study design including dose escalation / cohorts This is prospective pilot clinical trial of
      CNP in up to 30 patients with mTNBC
    
  